Advancing precision drug through innovative chemistry and advanced molecular technologies.
Integrated CDMO services spanning discovery, process development, custom synthesis and commercial manufacturing.
Delivering reliable CDMO solutions for innovative therapeutics worldwide.
Synthèse organique, synthèse à façon, développement de procédés et support au scale-up pour projets chimiques avancés.
Technologies de synthèse et d’analyse pour molécules complexes.
CHEMOS est un CDMO orienté synthèse, spécialisé en synthèse organique, synthèse à façon, développement de voies, développement de procédés, support au scale-up et accompagnement analytique.
Actualités, perspectives et mises à jour de CHEMOS.
Chongqing Xingcan Pharmaceutical Technology Co., Ltd. (CHEMOS) will participate in CPHI China 2026, held on 16–18 June 2026 at SNIEC, Shanghai (Booth No.: W9C42). The company will showcase its small molecule CDMO services, advanced drug delivery materials (lipids, PEG derivatives, linkers, functional excipients, etc.), and process development & manufacturing capabilities. CHEMOS warmly welcomes global partners, clients, and industry professionals to discuss custom synthesis, CDMO cooperation, material sourcing, scale-up manufacturing, and long-term strategic partnerships.
Lire la suiteTrifluoromethanesulfonic anhydride (Tf2O) is a highly efficient electrophilic activator in modern pharmaceutical synthesis, enabling precise introduction of fluorine atoms or trifluoromethyl groups into molecular scaffolds. This enhances metabolic stability, lipophilicity, and biological activity—key parameters in drug discovery. Its mechanism involves converting alcohols into reactive triflates, facilitating nucleophilic substitutions and cross-couplings. As a professional CDMO, we offer custom synthesis of Tf2O at ≥99% purity, scalable from gram to kilogram and beyond, with stringent quality control and fast delivery. Our services help pharmaceutical companies streamline fluorination steps, shorten synthetic routes, reduce costs, and accelerate the transition from lab to commercialization for novel fluorinated APIs.
Lire la suite
Antibody-drug conjugates (ADCs) enable targeted cancer therapy by linking antibodies to cytotoxic drugs, realizing Paul Ehrlich’s “magic bullet.” A recent review highlights linkers as key to stability and efficacy: cleavable linkers (e.g., enzyme-sensitive Val-Cit) enable precise tumor release, while non-cleavable linkers offer better plasma stability. Core strategies include site-specific conjugation, release triggers, and hydrophilic spacers to prevent aggregation. Advances feature dual-stimuli triggers, traceless release, branched structures, and AI tools like Linker-GPT. With 17 ADCs approved, challenges remain in immunogenicity, manufacturing, and resistance; future efforts focus on computational modeling and nanotechnology to expand applications beyond oncology.
De l’évaluation de voie au développement de procédé et au scale-up, CHEMOS soutient la synthèse à façon avec expérience R&D et base de production.
